Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS 株式レポート

時価総額:US$460.7m

Xeris Biopharma Holdings マネジメント

マネジメント 基準チェック /24

Xeris Biopharma Holdingsの CEO はJohn Shannonで、 Aug2024年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 1.85Mで、 30.9%給与と69.1%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.38%を直接所有しており、その価値は$ 1.74M 。経営陣と取締役会の平均在任期間はそれぞれ2年と3.1年です。

主要情報

John Shannon

最高経営責任者

US$1.8m

報酬総額

CEO給与比率30.9%
CEO在任期間less than a year
CEOの所有権0.4%
経営陣の平均在職期間2yrs
取締役会の平均在任期間3.1yrs

経営陣の近況

Recent updates

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Oct 25

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks

Sep 07
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Jun 04
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Mar 09
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Mar 06
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Jan 05
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

May 21

Xeris Continues To Execute And Build Long-Term Value Potential

Feb 22

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Dec 20

CEO報酬分析

Xeris Biopharma Holdings の収益と比較して、John Shannon の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$63m

Jun 30 2024n/an/a

-US$60m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$2mUS$571k

-US$62m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$71m

Mar 31 2023n/an/a

-US$78m

Dec 31 2022US$2mUS$549k

-US$95m

Sep 30 2022n/an/a

-US$133m

Jun 30 2022n/an/a

-US$137m

Mar 31 2022n/an/a

-US$138m

Dec 31 2021US$2mUS$528k

-US$123m

Sep 30 2021n/an/a

-US$94m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$80m

Dec 31 2020US$1mUS$474k

-US$91m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$119m

Mar 31 2020n/an/a

-US$129m

Dec 31 2019US$1mUS$444k

-US$126m

Sep 30 2019n/an/a

-US$113m

Jun 30 2019n/an/a

-US$95m

Mar 31 2019n/an/a

-US$73m

Dec 31 2018US$918kUS$369k

-US$60m

Sep 30 2018n/an/a

-US$49m

Jun 30 2018n/an/a

-US$42m

Mar 31 2018n/an/a

-US$34m

Dec 31 2017US$508kUS$219k

-US$27m

報酬と市場: Johnの 総報酬 ($USD 1.85M ) は、 US市場 ($USD 2.14M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Johnの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

John Shannon (62 yo)

less than a year

在職期間

US$1,848,153

報酬

Mr. John P. Shannon served as the President and Chief Operating Officer at Xeris Pharmaceuticals, Inc. since August 18, 2020 until October 2021 and since joining in February 2017 respectively and served as...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
John Shannon
CEO & Directorless than a yearUS$1.85m0.38%
$ 1.7m
Steven Pieper
Chief Financial Officer3.1yrsUS$1.61m0.95%
$ 4.4m
Beth Hecht
Chief Legal Officer & Corporate Secretary3.1yrsUS$1.13m0.22%
$ 996.4k
Paul Edick
Senior Advisorless than a yearUS$2.14m0.78%
$ 3.6m
Kenneth Johnson
Senior VP of Global Development & Medical Affairs3.1yrsUS$720.97k0.071%
$ 328.7k
Allison Wey
Senior Vice President of Investor Relations & Corporate Communications6.3yrsデータなしデータなし
Brian Conner
SVP of Quality and Chief Compliance & Risk Officerless than a yearデータなしデータなし
Kendal Korte
Senior Vice President of Human Resourcesless than a yearデータなしデータなし
Kevin McCulloch
Chief Commercial Officerno dataデータなし1.09%
$ 5.0m

2.0yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: XERSの経営陣は 経験豊富 とはみなされません ( 2年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
John Shannon
CEO & Directorless than a yearUS$1.85m0.38%
$ 1.7m
John Brooks
Scientific Advisory Board Memberno dataデータなしデータなし
Orville Kolterman
Member of Scientific Advisory Boardno dataデータなしデータなし
Jeffrey Sherman
Independent Director3.1yrsUS$175.75k0.080%
$ 370.1k
John Schmid
Lead Independent Director3.1yrsUS$218.25k0.059%
$ 273.0k
Garheng Kong
Independent Non-Executive Director3.1yrsUS$173.25k0.077%
$ 352.7k
W. Ward
Member of Scientific Advisory Boardno dataデータなしデータなし
Marla Persky
Independent Chairman3.1yrsUS$183.25k0.043%
$ 197.3k
Morey Haymond
Scientific Advisory Board Memberno dataデータなしデータなし
John Johnson
Independent Non-Executive Director3.1yrsUS$168.25k0.56%
$ 2.6m
Barbar-Jean Bormann-Kennedy
Independent Director3.1yrsUS$183.25k0.039%
$ 177.7k
Dawn Halkuff
Independent Director3.1yrsUS$175.75k0.042%
$ 194.4k

3.1yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: XERSの 取締役会経験豊富 であると考えられます ( 3.1年の平均在任期間)。